RADIANT clinical study is evaluating safety and performance outcomes of the Meridian® Valve and Pathfinder® II Delivery System for severe aortic stenosis

MINNEAPOLIS, Oct. 26, 2017 /PRNewswire/ — HLT, Inc., today announced that early data from the RADIANT clinical study will be presented during the Interventional Innovation: Emerging Devices and Technological Concepts session at the Transcatheter Cardiovascular Therapeutics Conference held Oct. 29Nov. 1, 2017 at the Colorado Convention Center in Denver, Colorado.

The RADIANT clinical study is evaluating safety and performance outcomes of the HLT’s Meridian Valve and Pathfinder II Delivery System for severe aortic stenosis. Study findings will be presented:

Monday, October 30, 2017

9:24 a.m.

Transcatheter aortic valve replacement with the HLT Meridian® Valve: Initial clinical experience


Mile High Ballroom 2A-3A, Ballroom Level


Josep Rodés-Cabau, M.D., director of Catheterization and Interventional Laboratories at the Quebec Heart and Lung Institute (Quebec City, Quebec, Canada)

Brad Fox, HLT and ACIST Medical president and chief executive officer commented, «The TCT presentation is a significant opportunity to share the initial clinical data and bring awareness of our unique technology to the broader interventional cardiology community.»

About HLT

HLT, Inc., is a clinical phase medical device company focused on transcatheter aortic valve replacement therapy. HLT’s Meridian® Transcatheter Aortic Valve is designed to conform to the natural structure of the heart, and the Pathfinder® II Delivery System is designed to provide physicians with the flexibility to reposition or fully retrieve the valve after assessing functionality.

HLT is headquartered in Maple Grove, Minn. Its team of employees works alongside its sister company ACIST Medical Systems, a pioneer and market leader of advanced contrast delivery and imaging systems for interventional cardiology. The privately held companies are part of the Bracco Group, an international leader in diagnostic imaging based in Milan, Italy. For more about HLT, visit www.hltmedical.com.

About Bracco Group
Bracco has headquarters in Milan, Italy, and was founded in 1927. It is active in the healthcare sector through Bracco Imaging (diagnostic imaging), ACIST Medical Systems and HLT (cardiology) and the Centro Diagnostico Italiano diagnostic clinic. It has around 3,400 employees and annual total consolidated revenues of over $1.38 billion USD (1.3 billion Euro). Bracco operates in more than 100 countries worldwide. To learn more about Bracco Group, visit www.bracco.com.

For Investigational Use Only. Not Available for Sale in Any Geography.

Contact:Peggy Malikowski
[email protected]


View original content with multimedia:http://www.prnewswire.com/news-releases/hlt-inc-to-provide-clinical-update-at-the-2017-transcatheter-cardiovascular-therapeutics-tct-conference-300542384.html